In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 341 to 350 of 401

TitleTypeExpected publication date
Suspected cancer updateQuality standardTBC
Suspected Cancer: recognition and referral (update)NICE guideline
Suspected sepsis: recognition, diagnosis and early managementNICE guideline
Suspected sepsis: recognition, diagnosis and early managementNICE guidelineTBC
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]Technology appraisal guidance
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413Technology appraisal guidance
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Technology appraisal guidanceTBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Technology appraisal guidance
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082]Technology appraisal guidance
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All